The CEO of Kleis Therapeutics will play a pivotal role in driving the company's strategic vision and achieving its key objectives. This includes leading the successful licensing and market entry of the third-generation TG2 inhibitor, overseeing critical drug development stages such as Phase 1 trials, and securing essential funding, including £23.4 million for ongoing research and development. The CEO will utilise their expertise in investments to manage investor relations and ensure the company's financial stability. They will also build and inspire a high-performing team, leveraging experience with spin-outs to foster collaboration and growth. Additionally, the CEO will develop and execute a long-term strategic vision to position Kleis Therapeutics as a leader in the antifibrotic market, enhancing the company’s presence and navigating regulatory and market challenges effectively.

Why does this opening exist?

The opening for a CEO at Kleis Therapeutics exists due to the company's need for strategic leadership to guide its growth and development as it advances through critical stages of drug development. As Kleis Therapeutics progresses with its third-generation TG2 inhibitor, a CEO is essential to drive the company's strategic vision and raising of funds and navigate the complex landscape of clinical trials and market entry.

With the company poised to complete Phase 1 trials and seek further funding, a CEO will provide the necessary leadership to oversee these processes, ensure alignment with corporate goals, and establish key partnerships. The CEO will also play a pivotal role in steering the company toward becoming a key player in the antifibrotic market, thus enabling Kleis Therapeutics to achieve its objectives and capitalise on its innovative research.

Key objectives

The key objectives for the CEO of Kleis Therapeutics are:

1. Strategic Licensing and Market Entry: The CEO will be responsible for leading the strategic licensing of the company’s third-generation TG2 inhibitor to the market. This involves negotiating partnerships and licensing agreements, ensuring that the drug reaches its commercial potential, and overseeing the transition from development to market.

2. Driving Clinical and Commercial Milestones: The CEO must guide the company through critical stages of drug development, including completing Phase 1 clinical trials, securing additional funding, and progressing through subsequent phases.

3. Investment and Fundraising: With previous experience in investments, the CEO will play a crucial role in securing necessary funding, including the £23.4 million required for lead optimisation, IND-enabling studies, and further clinical trials. This includes managing investor relations and ensuring the financial health of the company.

4. Strategic Vision and Market Positioning: The CEO will develop and execute the company’s long-term strategy, positioning Kleis Therapeutics as a key player in the antifibrotic market. This includes identifying and capitalising on market opportunities, navigating regulatory landscapes, and establishing the company’s presence in the industry.